Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.31 |
| ▸ | ITGAV | P06756 | 3/20 | 0.31 |
| ▸ | GGT1 | P19440 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5144359 | 1.00 | GABRR1 (0.32) | GABRR1LMNASLC22A6CA2CA4 | |
| SCHEMBL4030392 | 1.00 | GABRR1 (0.32) | GABRR1LMNASLC22A6CA2CA4 | |
| Aspartic Acid SCHEMBL7744939 | 0.89 | GRIK1 (0.35) | KMT2A | |
| SCHEMBL8364636 | 0.89 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL1880686 | 0.88 | CAMK2A (0.33) | GABRR1LMNAALDH1A1ITGB3ITGAV | |
| SCHEMBL8424379 | 0.88 | CAMK2A (0.33) | GABRR1LMNAALDH1A1ITGB3ITGAV | |
| SCHEMBL28308288 | 0.86 | GPR84 (0.34) | TDP1 | |
| Phenol SCHEMBL29187478 | 0.85 | ALDH1A1 (0.38) | LMNACA2CA4ALDH1A1MAPT | |
| SCHEMBL3441239 | 0.85 | ECE1 (0.38) | MEN1USP2ALDH1A1MAPTKMT2A | |
| SCHEMBL1221420 | 0.85 | ECE1 (0.38) | MEN1USP2ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007503382-A | — | — | 2007-02-22 | — | — | JP | claimed |
| US-20060281897-A1 | Potentialization of the activation of high molecular weight prodrugs | DIATOS S.A. (FR) | 2006-12-14 | — | — | US | claimed |
| EP-1701743-A2 | POTENTIATION OF THE ACTIVATION OF HIGH-MOLECULAR-MASS PRODRUGS | Diatos (FR) | 2006-09-20 | — | — | EP | claimed |
| WO-2005021043-A2 | HIGH-MOLECULAR-MASS PRODRUGS | DIATOS (FR) | 2005-03-10 | — | — | WO | claimed |
| US-20190031834-A1 | AMPHIPHILIC COPOLYMERS THEIR PREPARATION AND USE FOR THE DELIVERY OF DRUGS | DISTRETTO TECNOLOGICO SICILIA MICRO E NANO SISTEMI S.C.A.R.L. (IT) | 2019-01-31 | — | — | US | disclosed |
| EP-3209333-A1 | AMPHIPHILIC COPOLYMERS THEIR PREPARATION AND USE FOR THE DELIVERY OF DRUGS | Distretto Tecnologico Sicilia Micro e Nano Sistemi S.C.A.R.L. (IT) | 2017-08-30 | — | — | EP | disclosed |
| WO-2016055111-A1 | AMPHIPHILIC COPOLYMERS THEIR PREPARATION AND USE FOR THE DELIVERY OF DRUGS | DISTRETTO TECNOLOGICO SICILIA MICRO E NANO SISTEMI S.C.A.R.L. (IT) | 2016-04-14 | — | — | WO | disclosed |
| WO-2012098557-A1 | PEGYLATED GEMCITABINE DERIVATIVE AND PROCESS FOR PREPARING THE SAME | INSTITUTE OF LIFE SCIENCES (IN) | 2012-07-26 | — | — | WO | disclosed |
| EP-2124876-A1 | METHOD FOR THE COSMETIC TREATMENT OF KERATIN MATERIALS | L'Oreal (FR) | 2009-12-02 | — | — | EP | disclosed |
| EP-2124875-A2 | METHOD FOR THE COSMETIC TREATMENT OF KERATINIC MATERIALS AND COMPOSITION CONTAINING A GRAFTED AMINO ACID POLYMER | L'Oreal (FR) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008152669-A2 | COLLOIDAL VECTORS WITH POLYAMINOACID STRUCTURE FOR ORAL RELEASE OF PEPTIDES AND PROTEINS AND METHOD FOR THEIR PRODUCTION | UNIVERSITAT'DEGLI STUDI DI PALERMO (IT) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008125761-A1 | METHOD FOR THE COSMETIC TREATMENT OF KERATIN MATERIALS | L'OREAL (FR) | 2008-10-23 | — | — | WO | disclosed |
| WO-2000004877-A1 | SUPPOSITORY FORMULATIONS COMPRISING ANIONIC POLYSACCHARIDE | ALPENSTOCK HOLDINGS LIMITED (IE) | 2000-02-03 | — | — | WO | disclosed |
| EP-0403605-A4 | ELASTASE INHIBITING POLYMERS AND METHODS | UNIV KENTUCKY RES FOUND (US) | 1991-08-21 | — | — | EP | disclosed |
| EP-0396709-A4 | HUMAN LEUKOCYTE ELASTASE INHIBITORS AND METHODS OF PRODUCING AND USING SAME | — | 1991-05-22 | — | — | EP | disclosed |
| EP-0403605-A1 | ELASTASE INHIBITING POLYMERS AND METHODS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1990-12-27 | — | — | EP | disclosed |
| EP-0396709-A1 | HUMAN LEUKOCYTE ELASTASE INHIBITORS AND METHODS OF PRODUCING AND USING SAME | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1990-11-14 | — | — | EP | disclosed |
| EP-0368449-A2 | Elastase inhibiting polymers and methods to produce them | Digenis, George Alexander (US) | 1990-05-16 | — | — | EP | disclosed |
| EP-0367514-A2 | Human leukocyte elastase inhibitors and methods for producing and using same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1990-05-09 | — | — | EP | disclosed |
| WO-1990002558-A1 | ELASTASE INHIBITING POLYMERS AND METHODS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1990-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281897-A1 | Potentialization of the activation of high molecular weight prodrugs | CD44, MMP12, FOLH1 | GABRR1 4217/4885LMNA 1774/4885SLC22A6 1181/4885 |
| US-20190031834-A1 | AMPHIPHILIC COPOLYMERS THEIR PREPARATION AND USE FOR THE DELIVERY OF DRUGS | ABCB11, ABCB1, ABCB4 | GABRR1 2048/4885LMNA 321/4885SLC22A6 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.